Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Stemline Therapeutic (STML)

Stemline Therapeutic (STML)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 621,205
  • Shares Outstanding, K 52,511
  • Annual Sales, $ 43,220 K
  • Annual Income, $ -76,820 K
  • 60-Month Beta 1.78
  • Price/Sales 14.58
  • Price/Cash Flow N/A
  • Price/Book 4.20
Trade STML with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.59
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 06/05/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate -0.37
  • Number of Estimates 2
  • High Estimate -0.35
  • Low Estimate -0.39
  • Prior Year -0.42
  • Growth Rate Est. (year over year) +11.90%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.69 +1.20%
on 05/27/20
12.25 -3.43%
on 05/11/20
-0.35 (-2.87%)
since 05/08/20
3-Month
3.21 +268.54%
on 03/18/20
12.35 -4.21%
on 05/04/20
+6.79 (+134.72%)
since 03/09/20
52-Week
3.21 +268.54%
on 03/18/20
18.22 -35.07%
on 08/08/19
-2.65 (-18.30%)
since 06/07/19

Most Recent Stories

More News
SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, and QES Shareholders About Its Ongoing Investigations

NEW YORK, May 21, 2020 (GLOBE NEWSWIRE) --

STML : 11.83 (-1.42%)
PTLA : 18.03 (+0.22%)
QES : 0.9278 (-15.65%)
STEMLINE ALERT: Bragar Eagel & Squire, P.C. Investigates Sale of STML and Encourages Investors to Contact the Firm

NEW YORK, May 19, 2020 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the board members of Stemline Therapeutics,...

STML : 11.83 (-1.42%)
KLXE, FSB, PTLA, and STML SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

WILMINGTON, Del., May 19, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

KLXE : 7.34 (+0.14%)
FSB : 30.48 (-1.33%)
PTLA : 18.03 (+0.22%)
STML : 11.83 (-1.42%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

NEW YORK, NY / ACCESSWIRE / May 16, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP...

STML : 11.83 (-1.42%)
KLXE : 7.34 (+0.14%)
PTLA : 18.03 (+0.22%)
Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. (KLXE), Quintana Energy Services, Inc. (QES), Portola Pharmaceuticals, Inc. (PTLA), and Stemline Therapeutics, Inc. (STML)

NEW YORK, May 15, 2020 (GLOBE NEWSWIRE) --

KLXE : 7.34 (+0.14%)
QES : 0.9278 (-15.65%)
PTLA : 18.03 (+0.22%)
STML : 11.83 (-1.42%)
SHAREHOLDER ALERT: WeissLaw LLP Reminds STML, PTLA, QES, and TERP Shareholders About Its Ongoing Investigations

NEW YORK, May 14, 2020 (GLOBE NEWSWIRE) --

STML : 11.83 (-1.42%)
PTLA : 18.03 (+0.22%)
QES : 0.9278 (-15.65%)
TERP : 19.35 (-7.02%)
INVESTIGATION ALERT: Halper Sadeh LLP Investigates Whether the Following Mergers are Fair to Shareholders; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

NEW YORK, NY / ACCESSWIRE / May 13, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP...

STML : 11.83 (-1.42%)
KLXE : 7.34 (+0.14%)
PTLA : 18.03 (+0.22%)
KLXE, PTLA, STML, and TORC SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of Mergers

WILMINGTON, Del., May 12, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating:

KLXE : 7.34 (+0.14%)
PTLA : 18.03 (+0.22%)
STML : 11.83 (-1.42%)
TORC : 15.96 (-3.80%)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates the Following Companies; Investors are Encouraged to Contact the Firm - STML, KLXE, PTLA

NEW YORK, NY / ACCESSWIRE / May 11, 2020 / Halper Sadeh LLP, a global investor rights law firm, continues to investigate whether the following proposed mergers are fair to shareholders. Halper Sadeh LLP...

STML : 11.83 (-1.42%)
KLXE : 7.34 (+0.14%)
PTLA : 18.03 (+0.22%)
Lifshitz Law Firm, P.C. Announces Investigation of KLX Energy Services Holdings, Inc. (KLXE), Portola Pharmaceuticals, Inc. (PTLA), Stemline Therapeutics, Inc. (STML) and Zuora, Inc. (ZUO)

NEW YORK, May 11, 2020 (GLOBE NEWSWIRE) -- KLX Energy Services Holdings, Inc. (KLXE)

KLXE : 7.34 (+0.14%)
PTLA : 18.03 (+0.22%)
STML : 11.83 (-1.42%)
ZUO : 9.07 (+2.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 12.20
1st Resistance Point 12.01
Last Price 11.83
1st Support Level 11.73
2nd Support Level 11.64
3rd Support Level N/A

See More

52-Week High 18.22
Fibonacci 61.8% 12.49
Last Price 11.83
Fibonacci 50% 10.72
Fibonacci 38.2% 8.94
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar